secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-07-28T11:16:15+00:00
Accession:  0001140361-26-029837
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics gets FDA Type A minutes; no clinical deficiencies; adds U.S. manufacturing site for GTx-104
--------------------------------------------------------------------------------

- FDA did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data.
- CRL items relate to cGMP compliance at contract manufacturer, leachables data, and excipient toxicology risk assessments.
- Company pursuing dual-source manufacturing strategy, adding a U.S.-based contract manufacturer.
- No single path to resubmission designated; resubmission may be supported by either or both manufacturers.
- STRIVE-ON trial met primary endpoint with 19% reduction in clinically significant hypotension vs oral nimodipine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/0001140361-26-029837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-029837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer